A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display

mAbs

Volumn 7, Issue 1, 2015, Pages 138-151

  Schröter, Christian ^a,b   Günther, Ralf ^b   Rhiel, Laura ^b   Becker, Stefan ^b   Toleikis, Lars ^b   Doerner, Achim ^b   Becker, Janine ^a   Schönemann, Andreas ^b   Nasu, Daichi ^a   Neuteboom, Berend ^c   Kolmar, Harald ^a   Hock, Björn ^b  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b Merck Serono GmbH   (Germany)

^c EMD SERONO INC   (United States)

Author keywords

Adalimumab; Antibody engineering; Fab display; pH dependent antigen binding; pH switch; Protein engineering; Yeast surface display

Indexed keywords

ADALIMUMAB; HISTIDINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION; HISTIDINE SCANNING LIBRARY; IMMUNOGLOBULIN VARIABLE REGION; PEPTIDE LIBRARY; PH; YEAST; CHEMISTRY; GENE LIBRARY; GENETICS; HUMAN; PROTEIN TERTIARY STRUCTURE; SACCHAROMYCES CEREVISIAE;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL, HUMANIZED; GENE LIBRARY; HISTIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; PROTEIN STRUCTURE, TERTIARY; SACCHAROMYCES CEREVISIAE;

EID: 84921327269     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2014.985993     Document Type: Article

References (51)

1. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090-7; PMID:22294692; http://dx.doi.org/10.1074/jbc.M111.319764
2. Gera N, Hill AB, White DP, Carbonell RG, Rao BM. Design of pH sensitive binding proteins from the hyperthermophilic Sso7d scaffold. PLoS One 2012; 7: e48928; PMID:23145025; http://dx.doi.org/10.1371/journal.pone.0048928
3. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.org/10.1038/nbt.1691
4. Sarkar CA, Lowenhaupt K, Horan T, Boone TC, Tidor B, Lauffenburger DA. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching." Nat Biotechnol 2002; 20:908-13; PMID:12161759; http://dx.doi.org/10.1038/nbt725
5. Tsukamoto M, Watanabe H, Ooishi A, Honda S. Engineered protein A ligands, derived from a histidinescanning library, facilitate the affinity purification of IgG under mild acidic conditions. J Biol Eng 2014; 8:15; PMID:25057290; http://dx.doi.org/10.1186/1754-1611-8-15
6. French AR, Tadaki DK, Niyogi SK, Lauffenburger DA. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J Biol Chem 1995; 270:4334-40; PMID:7876195; http://dx.doi.org/10.1074/jbc.270.9.4334
7. Kulkarni MV, Tettamanzi MC, Murphy JW, Keeler C, Myszka DG, Chayen NE, Lolis EJ, Hodsdon ME. Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation. J Biol Chem 2010; 285:38524-33; PMID:20889499; http://dx.doi.org/10.1074/jbc.M110.172072
8. Maeda K, Kato Y, Sugiyama Y. pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. J Control Release 2002; 82:71-82; PMID:12106978; http://dx.doi.org/10.1016/S0168-3659(02)00126-8
9. Lauffenburger DA, Fallon EM, Haugh JM. Scratching the (cell) surface: cytokine engineering for improved ligand/receptor trafficking dynamics. Chem Biol 1998; 5:R257-63; PMID:9818145; http://dx.doi.org/10.1016/S1074-5521(98)90110-7
10. Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 1991; 2:599-612; PMID:1777504
11. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 1998; 273:13819-27; PMID:9593726; http://dx.doi.org/10.1074/jbc.273.22.13819
12. Cama A, Sierra ML, Kadowaki T, Kadowaki H, Quon MJ, Rudiger HW, Dreyer M, Taylor SI. Two mutant alleles of the insulin receptor gene in a family with a genetic form of insulin resistance: a 10 base pair deletion in exon 1 and a mutation substituting serine for asparagine-462. Hum Genet 1995; 95:174-82; PMID:7860063; http://dx.doi.org/10.1007/BF00209397
13. Fallon EM, Liparoto SF, Lee KJ, Ciardelli TL, Lauffenburger DA. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J Biol Chem 2000; 275:6790-7; PMID:10702236; http://dx.doi.org/10.1074/jbc.275.10.6790
14. Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME. The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 2007; 46:2398-410; PMID:17279774; http://dx.doi.org/10.1021/bi061958v
15. Yamamoto T, Chen HC, Guigard E, Kay CM, Ryan RO.Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor. Biochemistry 2008; 47:11647-52; PMID:18847225; http://dx.doi.org/10.1021/bi801117t
16. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
17. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989; 337:184-7; PMID:2911353; http://dx.doi.org/10.1038/337184a0
18. Tesar DB, Bjorkman PJ. An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Curr Opin Struct Biol 2010; 20:226-33; PMID:20171874; http://dx.doi.org/10.1016/j.sbi.2010.01.010
19. Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta 2014; 11:1943-50; http://dx.doi.org/10.1016/j.bbapap.2014.08.003
20. Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L, et al. The effect of pH dependence of anti-body-antigen interactions on subcellular trafficking dynamics. MAbs 2013; 5:851-9; PMID:24492341; http://dx.doi.org/10.4161/mabs.26389
21. Tanford C. Protein denaturation. C. Theoretical models for the mechanism of denaturation. Adv Protein Chem 1970; 24:1-95; PMID:4912353; http://dx.doi.org/10.1016/S0065-3233(08)60241-7
22. Warwicker J. A theoretical study of the acidification of the rhinovirus capsid. FEBS Lett 1989; 257:403-7; PMID:2555222; http://dx.doi.org/10.1016/0014-5793(89)81582-0
23. Warwicker J. Model for the differential stabilities of rhinovirus and poliovirus to mild acidic pH, based on electrostatics calculations. J Mol Biol 1992; 223:247-57; PMID:1309885; http://dx.doi.org/10.1016/0022-2836(92)90729-4
24. Kampmann T, Mueller DS, Mark AE, Young PR, Kobe B. The Role of histidine residues in low-pH-mediated viral membrane fusion. Structure 2006; 14:1481-7; PMID:17027497; http://dx.doi.org/10.1016/j.str.2006.07.011
25. Murtaugh ML, Fanning SW, Sharma TM, Terry AM, Horn JR. A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Sci 2011; 20:1619-31; PMID:21766385; http://dx.doi.org/10.1002/pro.696
26. Ito W, Sakato N, Fujio H, Yutani K, Arata Y, Kurosawa Y. The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values. FEBS Lett 1992; 309:85-8; PMID:1511750; http://dx.doi.org/10.1016/0014-5793(92)80745-3
27. Strauch EM, Fleishman SJ, Baker D. Computational design of a pH-sensitive IgG binding protein. Proc Natl Acad Sci USA 2014; 111:675-80; PMID:24381156; http://dx.doi.org/10.1073/pnas.1313605111
28. Spassov VZ, Yan L. pH-selective mutagenesis of protein-protein interfaces: in silico design of therapeutic antibodies with prolonged half-life. Proteins 2013; 81:704-14; PMID:23239118; http://dx.doi.org/10.1002/prot.24230
29. Doerner A, Rhiel L, Zielonka S, Kolmar H. Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett 2014; 588:278-87; PMID:24291259; http://dx.doi.org/10.1016/j.febslet.2013.11.025
30. Traxlmayr MW, Lobner E, Hasenhindl C, Stadlmayr G, Oostenbrink C, Ruker F, Obinger C. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution. Biotechnol J 2014; 9:1013-22; PMID:24964247; http://dx.doi.org/10.1002/biot.201300483
31. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79; PMID:18155297; http://dx.doi.org/10.1016/j.pharmthera.2007.10.001
32. den BA, van de Putte L, Rau R, Schattenkirchner M, Van RP, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factoralpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J.Rheumatol 2002; 29:2288-98; PMID:12415583
33. Arnold FH. Directed evolution: creating biocatalysts for the future. Chem Eng Sci 1996; 51:5091-102; http://dx.doi.org/10.1016/S0009-2509(96)00288-6
34. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553
35. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-16; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002
36. Estep P, Reid F, Nauman C, Liu Y, Sun T, Sun J, Xu Y. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs 2013; 5:270-8; PMID:23575269; http://dx.doi.org/10.4161/mabs.23049
37. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011; 39:1469-77; PMID:21610128; http://dx.doi.org/10.1124/dmd.111.039453
38. Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38:12639-47; PMID:10504233; http://dx.doi.org/10.1021/bi9913505
39. Pepper LR, Cho YK, Boder ET, Shusta EV. A decade of yeast surface display technology: where are we now? Comb Chem High Throughput Screen 2008; 11:127-34; PMID:18336206; http://dx.doi.org/10.2174/138620708783744516
40. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J Biol Chem 2013; 288:27059-67; PMID:23943614; http://dx.doi.org/10.1074/jbc.M113.491530
41. Johnson G, Wu TT. Kabat Database and its applications: future directions. Nucleic Acids Res 2001; 29:205-6; PMID:11125092; http://dx.doi.org/10.1093/nar/29.1.205
42. Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013; 56:660-74; PMID:23917469; http://dx.doi.org/10.1016/j.molimm.2013.05.008
43. Hopkins CR, Trowbridge IS. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol 1983; 97:508-21; PMID:6309862; http://dx.doi.org/10.1083/jcb.97.2.508
44. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666; http://dx.doi.org/10.4049/jimmunol.172.4.2021
45. Rakestraw JA, Sazinsky SL, Piatesi A, Antipov E, Wittrup KD. Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in Saccharomyces cerevisiae. Biotechnol Bioeng 2009; 103:1192-201; PMID:19459139; http://dx.doi.org/10.1002/bit.22338
46. Suga M, Hatakeyama T. High-efficiency electroporation by freezing intact yeast cells with addition of calcium. Curr Genet 2003; 43:206-11; PMID:12684838
47. Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel 2010; 23:155-9; PMID:20130105; http://dx.doi.org/10.1093/protein/gzq002
48. Bubeck P, Winkler M, Bautsch W. Rapid cloning by homologous recombination in vivo. Nucleic Acids Res 1993; 21:3601-2; PMID:8346047; http://dx.doi.org/10.1093/nar/21.15.3601
49. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 2004; 332:153-9; PMID:15301960; http://dx.doi.org/10.1016/j.ab.2004.04.031
50. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003; 24:1999-2012; PMID:14531054; http://dx.doi.org/10.1002/jcc.10349
51. Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 2004; 57:678-83; PMID:15390263; http://dx.doi.org/10.1002/prot.20251